Fluticasone Propionate And Salmeterol Powder
Product Images NDC 0054-0327

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 0054-0327). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figurec.jpg (Figurec)

An instructional illustration showing how to hold and operate a respiratory inhaler device for administering powdered fluticasone propionate and salmeterol. The image depicts hands gripping the inhaler with an arrow indicating a twisting or turning motion on the device.*

FDA Label Image

Figuref.jpg (Figuref)

An instructional illustration showing a person holding a respiratory inhalation powder device with both hands, demonstrating a counter window displaying the number 59 and an arrow indicating a twisting motion of the bottom part of the inhaler, likely to prepare the dose for inhalation.*

FDA Label Image

Figureh.jpg (Figureh)

An instructional illustration of a respiratory inhalation device showing a close-up of a dose counter window displaying the number 5 in red. The device appears designed for inhalation of powder medication, likely fluticasone propionate and salmeterol.*

FDA Label Image

Fluticasone-propionate-chemical.jpg (Fluticasone Propionate Chemical)

Chemical structure of fluticasone propionate, an active ingredient in the inhalation powder combination product fluticasone propionate and salmeterol.*

FDA Label Image

Image-100-50-mcg (Image 01)

Label for fluticasone propionate and salmeterol inhalation powder, USP, strength 100 mcg/50 mcg. The label indicates it is for oral inhalation only, distributed by Hikma Pharmaceuticals USA Inc. It describes the product as one inhalation device containing 1 foil strip of 60 blisters, with storage instructions and usage warnings. The label includes an NDC number and barcode.*

FDA Label Image

Image-250-50-mcg (Image 02)

Fluticasone propionate and salmeterol inhalation powder, USP 250 mcg/50 mcg strength. Packaging label shows 1 inhalation device containing 1 foil strip with 60 blisters. Distributed by Hikma Pharmaceuticals USA Inc. Label includes storage instructions and usage warnings for oral inhalation only.*

FDA Label Image

Image 03

A line graph showing percentage change in FEV1 over time in days and weeks for three treatment groups: fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg, fluticasone propionate 250 mcg, and placebo. The graph includes data points from day 1 through week 24 and an endpoint, with corresponding sample sizes for each group at various time points.*

FDA Label Image

Image 04

A line graph showing the percentage change in FEV1 over 24 weeks for three groups: Fluticasone Propionate and Salmeterol Inhalation Powder 250 mcg/50 mcg twice daily, Salmeterol 50 mcg twice daily, and placebo. The x-axis represents weeks, and the y-axis shows % change in FEV1. Data points depict sustained improvements with fluticasone and salmeterol compared to the other groups. Sample sizes for each group are provided at several time points below the graph.*

FDA Label Image

Image 05

Line graph showing % change in FEV1 over 12 weeks and endpoint for treatment groups: fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The graph compares the respiratory function outcomes for these groups during the study period.*

FDA Label Image

Image 06

A line graph showing percent change in FEV1 over 12 hours on the first treatment day for four groups: fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The combined treatment group demonstrates the highest peak increase and sustained improvement.*

FDA Label Image

Image 07

A line graph showing percentage change in FEV1 relative to Day 1 baseline on the last treatment day (Week 12) over 12 hours post-dose. Four treatment groups are compared: Fluticasone Propionate and Salmeterol Inhalation Powder 100 mcg/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone Propionate 100 mcg twice daily, and Placebo.*

FDA Label Image

Image1.jpg (Image1)

An instructional diagram of a respiratory inhaler device labeled with fluticasone propionate and salmeterol 100 mcg/50 mcg powders. The image highlights key parts: an outer case, mouthpiece, thumb grip, lever, and a dose counter showing 60 doses remaining.*

FDA Label Image

Salmeterol-xinafoate-chemical.jpg (Salmeterol Xinafoate Chemical)

Chemical structure of the active ingredients fluticasone propionate and salmeterol depicted as two connected molecular diagrams representing their chemical formulas.*

FDA Label Image

Ww-image-2.jpg (Ww Image 2)

Illustration showing a person holding a respiratory inhaler device for fluticasone propionate and salmeterol powder. The image depicts hands gripping the inhaler and an arrow indicating a twisting or rotating motion, likely demonstrating how to activate or prepare the device for use.*

FDA Label Image

Ww-image-4.jpg (Ww Image 4)

An instructional illustration shows a person holding a respiratory inhaler device near their mouth, demonstrating the proper technique for using the inhaler to administer fluticasone propionate and salmeterol powder for inhalation.*

FDA Label Image

Ww-image-5.jpg (Ww Image 5)

An illustration showing a person using a respiratory inhalation powder device. The individual is holding the inhaler to their mouth, demonstrating the proper inhalation technique for administering the medication.*

FDA Label Image

Ww-image-7.jpg (Ww Image 7)

An illustration showing a person rinsing their mouth over a sink, with a glass of water placed nearby on the counter. This image likely depicts oral rinsing or spitting, commonly advised after using respiratory inhalation powders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.